antiplatelet agent

antiplatelet agent

Therapeutics Any agent–eg, aspirin, that ↓ platelet clumping and clotting

an·ti·plate·let a·gent

(an'tē-plāt'lĕt ā'jĕnt)
Agent that inhibits platelet aggregation and thus reduces the risk of thrombus formation.
References in periodicals archive ?
Furthermore, there is a gap between guidelines and clinical practice, (7) as substantial numbers of patients continue to be treated with an oral anticoagulant and antiplatelet agent. The use of an antiplatelet agent after PCI reduces the risk of ischaemic or atherothrombotic events(8) but raises the risk of bleeding".
Aspirin is economically priced antiplatelet agent which is extremely safe and effective.
Aspirin inhibits platelet cyclooxygenase and thromboxane A2 and has been the most widely used antiplatelet agent. Dipyridamole is an inhibitor of phosphodiesterase.
Looking at all patients taking warfarin (regardless of whether or not they were also taking an NSAID or antiplatelet agent), PPI co-therapy reduced the risk of hospitalization for upper GI bleeding by 24% (adjusted hazard ratio [HR]=0.76; 95% confidence interval [CI], 0.63 to 0.91), which translates into 29 fewer hospitalizations per 10,000 person-years.
When a patient is on an anticoagulant or antiplatelet agent, it takes longer for primary hemostasis to occur; subsequently bleeding time is prolonged.
It proposed a clinical response to Clopidogrel, an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease.
In this sub analysis for a new antiplatelet agent, this combination therapy did not prove to be useful, on the contrary, it produced more harm.
Ticagrelor: A Novel Reversible Oral Antiplatelet Agent. Cardiol Rev.
In a prospective study with 1,358 patients presenting with acute coronary syndromes to the emergency department, with a 30-day follow-up, 5.4 % (n = 73) had stopped taking their oral antiplatelet agent 3 weeks before the acute episode, and the majority (64 %) had done so on the doctor's orders because of an upcoming elective procedure.
A large clinical trial (n=1358) involving hospitalized patients admitted with an acute coronary syndrome placed patients into three groups: those who had never taken an oral antiplatelet agent [nonusers] (n=930), those with a history of prior use (n=355) and those who had recently discontinued use (n=73).